The limitations of conventional mass spec for high-throughput screening



November 11, 2016

  • Share
  • Jonathan Wingfield, Principal Scientist, AstraZeneca, describes some of the limitations of conventional mass spectrometry for high-throughput screening

    Drug DiscoveryMass Spectrometry

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.